查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947969

口服補體抑制劑市場依藥物類別、分子標靶和治療應用分類，全球預測（2026-2032年）

Oral Complement Inhibitors Market by Drug Class, Molecular Target,, Therapeutic Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，口服補體抑制劑市場價值將達到 22 億美元，到 2026 年將成長至 23 億美元，到 2032 年將達到 33.8 億美元，複合年成長率為 6.32%。

關鍵市場統計數據
基準年 2025 22億美元
預計年份：2026年 23億美元
預測年份 2032 33.8億美元
複合年成長率 (%) 6.32%

口服補體抑制劑的策略性應用：聚焦臨床原理、研發重點和相關人員，助力計畫成功

補體標靶治療領域正迅速發展，口服藥物因其在臨床醫生、支付方和尋求腸外療法替代方案的患者中日益成長的關注度而備受青睞。本執行摘要概述了口服補體抑制劑的臨床原理、治療標靶以及影響其研發和商業化路徑的相關人員期望，從而為其提供策略背景。文中重點介紹了關鍵項目優先事項，包括對補體介導疾病的療效、長期給藥的安全性、患者使用便利性以及與現有治療標準的兼容性。

藥物設計、以病人為中心的照護模式以及監管機構對真實世界數據的接受程度的進步，正在如何重塑口服補體抑制劑的格局

過去幾年，科學知識、藥物設計和醫療服務領域的變革性變化共同重塑了補體抑制劑的競爭格局。分子藥理學和轉化免疫學的進步明確了標靶選擇，使得設計口服生物利用度高、能更特異性調節補體活化的小分子成為可能。同時，藥物化​​學的進步提高了口服暴露量、代謝穩定性和組織分佈，這些進步共同降低了以往針對補體的小分子藥物研發所面臨的障礙。

評估近期美國關稅調整和貿易政策轉變如何推動專科藥品供應鏈多元化和製造地結構重組。

2025年的貿易政策發展為生物製藥和小分子治療藥物（包括口服補體抑制劑）的生產商和經銷商帶來了新的考量。進口關稅表和執法通訊協定的調整增加了跨境供應鏈的行政負擔，尤其是在從國際供應商採購活性藥物成分（API）方面。因此，各公司正在重新評估其籌資策略，篩選合格的供應商，並實現製造地多元化，以降低單一來源風險並減少潛在的前置作業時間波動。

詳細的細分分析將治療適應症和作用機制的考慮因素與口服補劑方案中細緻的患者群體和臨床策略聯繫起來。

基於治療用途的細分分析顯示，臨床重點主要集中在非典型溶血性尿毒症候群、遺傳性血管性水腫和陣發性睡眠性血尿症。每種疾病都為藥物研發和商業化帶來了獨特的挑戰。非典型溶血性尿毒症候群的研發項目需要針對成人和兒童患者群體進行客製化，並充分考慮劑量考量、安全性監測需求和長期腎功能預後指標的差異。遺傳性血管性水腫的研發項目分為急性治療方案和預防方案。急性治療方案要求起效迅速且療效持久，而預防方案則優先考慮長期用藥的耐受性和依從性。陣發性睡眠性血尿症的研發項目也同樣分為成人和兒童兩個部分，臨床醫生擴大評估口服維持治療的可行性，無論是作為單藥治療還是與現有標準療法聯合治療。

區域監管差異、支付方預期和臨床基礎設施如何塑造美洲、歐洲、中東和非洲以及亞太市場的差異化策略

區域趨勢對口服補體抑制劑，美洲、歐洲、中東和非洲以及亞太地區之間存在顯著差異。在美洲，監管機構和臨床界對有嚴格療效和安全性數據支持的創新口服療法持開放態度，而支付方則越來越要求藥物在改善患者體驗和降低總醫療成本方面取得切實進展，以此作為藥物獲批上市的依據。因此，申辦者通常會優先考慮全面的療效數據和衛生經濟模型，以推動市場進入的討論。

來自策略聯盟、敏捷生物技術公司和綜合證據生成方法的日益激烈的競爭將推動專案差異化。

口服補體抑制劑領域的產業活動呈現多元化態勢，既有成熟的製藥公司，也有生技創新企業和專注於研發的專業公司，它們各自推進不同的產品線。主要企業正積極建立策略聯盟，將補體生物學的基礎專長與小分子化學、製劑科學和商業性執行的優勢結合。這些合作通常包括共同開發契約、許可協議和共同促銷框架，旨在加速臨床項目並擴大地域覆蓋範圍。

整合臨床設計、供應鏈韌性和支付方參與，加速口服補充療法開發和推廣的實用策略建議

產業領導者必須採取協作方式，整合科學、商業性和營運方面的努力，以加速口服補體抑制劑的研發和應用。首先，應優先進行臨床項目，將生物標記指導的患者選擇與對臨床醫生、監管機構和支付方有意義的終點指標相結合，以提高臨床區分的清晰度和可靠性。其次，應儘早投資於製劑和藥物動力學最佳化，以確保口服候選藥物能夠在不影響安全性的前提下實現標靶結合，並考慮與現有標準療法互補的聯合治療策略。

我們採用綜合性的多源調查方法，結合專家對話、監管和臨床文獻綜合以及三角情境分析，來支持我們的策略結論。

本分析採用了多方面的調查方法，結合了專家訪談、對公開臨床試驗註冊庫和監管出版物的系統性回顧，以及對同行評審的轉化醫學和臨床文獻的綜合分析。研究人員從血液學和免疫學臨床醫生、具有補體系統經驗的藥理學專家、供應鏈專家和支付方代表處收集了主要的定性數據，以使研究結果與實際情況相符。此外，研究人員還進行了二次研究，包括分析近期科學會議、監管指導文件以及已發表的安全性和有效性報告，確保了研究結果的技術基礎。

將策略重點與科學檢驗、符合支付方利益的證據產生以及營運韌性相結合，以充分發揮口服補體療法的潛力。

總之，口服補體抑制劑代表了補體介導疾病治療管理的革命性轉變，並有望提高治療的便利性、依從性和門診治療模式。標靶檢驗和口服藥物設計的科學進步，以及監管機構和支付方對以患者為中心的真實世界證據日益成長的認可，正推動對這些治療方法的持續投資。然而，成功的臨床轉化需要密切關注患者分層、長期安全性監測以及與支付方價值框架的契合。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 口服補體抑制劑市場（依藥物類別分類）

  • 阿巴科潘
  • 伊普塔科潘

9. 口服補體抑制劑市場－基於分子標靶的分類

  • D因子抑制劑
  • B 因子抑制劑
  • C5抑制劑

第10章：口服補體抑制劑市場

  • 血液疾病
  • 腎臟疾病
  • 神經系統疾病
  • 眼科疾病

11. 依治療應用分類的口服補體抑制劑市場

  • 非典型溶血性尿毒症候群
    • 成年患者
    • 兒童患者
  • 遺傳性血管性水腫
    • 急性治療
    • 預防性治療
  • 陣發性睡眠性血尿症
    • 成年患者
    • 兒童患者

12. 各地區口服補體抑制劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 口服補體抑制劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國口服補體抑制劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國補體抑制劑市場

第16章：中國補體抑制劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • Biocryst Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Omeros Corporation
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Swedish Orphan Biovitrum AB
  • UCB SA
Product Code: MRR-4F7A6D4FB6B3

The Oral Complement Inhibitors Market was valued at USD 2.20 billion in 2025 and is projected to grow to USD 2.30 billion in 2026, with a CAGR of 6.32%, reaching USD 3.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.20 billion
Estimated Year [2026] USD 2.30 billion
Forecast Year [2032] USD 3.38 billion
CAGR (%) 6.32%

A strategic introduction to oral complement inhibitors highlighting clinical rationale, development priorities, and stakeholder expectations shaping program success

The landscape of complement-targeted therapeutics is evolving rapidly as oral modalities attract heightened interest from clinicians, payers, and patients seeking alternatives to parenteral therapies. This executive summary introduces the strategic context for oral complement inhibitors by outlining the clinical rationale, therapeutic targets, and stakeholder expectations that shape development and commercialization pathways. It frames key programmatic priorities-efficacy in complement-mediated diseases, safety across chronic administration, ease of use for patients, and compatibility with existing standard-of-care treatments.

Given the heterogeneity of conditions driven by complement dysregulation, industry efforts increasingly emphasize precision in mechanism selection and patient stratification. Emerging oral agents aim to address unmet needs across rare, immune-mediated hematologic and vascular disorders by offering improved convenience and potential for at-home administration. As companies advance candidates through clinical development, regulatory pathways and real-world evidence generation play a central role in de-risking programs and demonstrating value to payers. Consequently, frontrunners must align clinical trial designs with meaningful clinical endpoints, robust safety monitoring plans, and pragmatic measures of patient-centric outcomes to accelerate adoption.

How advances in drug design, patient-centric care models, and regulatory acceptance of real-world evidence are reshaping the oral complement inhibitors landscape

Over the past several years, transformative shifts in scientific understanding, drug design, and healthcare delivery have converged to reshape the competitive environment for complement inhibitors. Advances in molecular pharmacology and translational immunology have clarified target selection, enabling the design of orally bioavailable small molecules that modulate complement activation with greater specificity. Parallel progress in medicinal chemistry has improved oral exposure, metabolic stability, and tissue distribution, which collectively lower the developmental barriers previously associated with complement-targeted small molecules.

Concurrently, the clinical paradigm is shifting from episodic, hospital-based interventions toward chronic, outpatient management. This shift is driven by a stronger emphasis on patient quality of life, the operational strain on infusion centers, and a desire to reduce caregiver burden. As a result, manufacturers are prioritizing formulations that support at-home dosing and treatment adherence. Moreover, regulatory authorities are increasingly receptive to patient-reported outcomes and real-world evidence as components of approval and labeling discussions, prompting sponsors to integrate pragmatic endpoints and decentralized trial elements early in program design. Thus, the combination of scientific feasibility and healthcare delivery momentum is accelerating the transition from injectable biologics to oral therapeutic options.

Assessing how recent US tariff adjustments and trade policy shifts are prompting supply chain diversification and manufacturing realignment for specialty therapeutics

Trade policy developments in 2025 have introduced new considerations for manufacturers and distributors of biologics and small-molecule therapies, including oral complement inhibitors. Adjustments to import duty schedules and enforcement protocols have increased the administrative burden for cross-border supply chains, particularly for active pharmaceutical ingredients sourced from international suppliers. As a result, companies are re-evaluating procurement strategies, qualifying additional suppliers, and diversifying manufacturing footprints to reduce exposure to single-source risks and to mitigate potential lead-time variability.

In response, commercial and supply chain teams are placing greater emphasis on nearshoring, regional manufacturing partnerships, and redundant inventory planning. These operational shifts aim to maintain continuity of supply while preserving pricing flexibility and payer agreements. At the same time, firms are strengthening regulatory and customs compliance functions to expedite clearance and reduce disruption. Given these dynamics, strategic planning must account for tariff-related friction in contracting and distribution negotiations, and stakeholders should prioritize scenario-based contingency planning to preserve patient access and prevent interruptions in therapy deployment.

Detailed segmentation insights link therapeutic indications and mechanism considerations to patient cohorts and clinical strategy nuances for oral complement programs

Segmentation analysis based on therapeutic application reveals a concentrated clinical focus on atypical hemolytic uremic syndrome, hereditary angioedema, and paroxysmal nocturnal hemoglobinuria, each presenting distinct development and commercialization imperatives. Within atypical hemolytic uremic syndrome, development programs must address both adult and pediatric patient populations, recognizing divergent dosing considerations, safety surveillance needs, and long-term renal outcome measures. Hereditary angioedema programs divide into acute treatment paradigms and prophylactic approaches, with acute therapies requiring rapid onset and predictable durability while prophylactic agents prioritize tolerability and adherence for chronic use. Paroxysmal nocturnal hemoglobinuria programs similarly segment into adult and pediatric cohorts, where clinicians increasingly assess the feasibility of oral maintenance therapy either as monotherapy or in combination with existing standards of care.

When considering mechanism of action, the current analytical framework includes C1 inhibitors as a primary category. Although historically administered parenterally, C1-targeted strategies are being re-examined in light of formulation science and mechanistic validation to determine whether oral delivery can achieve meaningful target engagement with acceptable safety margins. Across both therapeutic and mechanistic segments, patient selection, biomarker-driven endpoints, and age-specific safety profiles remain central to clinical strategy. Therefore, sponsors should align trial design with the nuances of each therapeutic subgroup to maximize clinical relevance and to support differentiated value propositions in payer and clinical discussions.

How regional regulatory variability, payer expectations, and clinical infrastructure shape differentiated strategies across Americas, EMEA, and Asia-Pacific markets

Regional dynamics exert a significant influence on development timelines, regulatory strategies, and commercial rollouts for oral complement inhibitors, with notable variation across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, regulatory agencies and clinical communities have shown a readiness to engage with innovative oral approaches when supported by rigorous efficacy and safety data, and payer systems increasingly look for demonstrable improvements in patient experience and total cost of care to justify formulary placement. Consequently, sponsors often prioritize comprehensive outcomes data and health economic models to facilitate market access discussions.

Within Europe Middle East & Africa, diverse regulatory frameworks and reimbursement pathways necessitate tailored country-level strategies. Stakeholders must navigate heterogeneous health technology assessment expectations, varying levels of rare disease infrastructure, and differing clinical practice patterns. Early alignment with regional opinion leaders and HTA bodies supports more efficient value demonstration. In the Asia-Pacific region, rapid clinical trial enrollment capacity, growing investment in local manufacturing, and evolving regulatory frameworks create opportunities for accelerated evidence generation and regional supply agreements. That said, successful commercialization in this region often requires culturally attuned patient engagement strategies and careful consideration of local reimbursement mechanisms.

Competitive dynamics driven by strategic alliances, nimble biotech innovators, and integrated evidence generation approaches shaping program differentiation

Industry activity around oral complement inhibitors reflects a mix of incumbent pharmaceutical companies, biotechnology innovators, and specialty developers advancing differentiated pipelines. Leading organizations are forming strategic alliances to combine foundational expertise in complement biology with strengths in small-molecule chemistry, formulation science, and commercial execution. These collaborations often include joint development agreements, licensing arrangements, and co-promotion frameworks designed to accelerate clinical programs and broaden geographic reach.

At the same time, nimble, clinical-stage companies are leveraging focused indications and biomarker-driven trial designs to create clear proof-of-concept inflection points that can attract partnerships or acquisition interest. Across the competitive landscape, successful programs demonstrate strong translational linkages between preclinical pharmacology and clinical endpoints, robust safety surveillance strategies for chronic administration, and data packages that address payer evidence needs. Strategic differentiation also emerges from integrated patient support services, digital adherence tools, and real-world data collection plans that enhance both clinician and payer confidence in long-term outcomes.

Actionable strategic recommendations for aligning clinical design, supply chain resilience, and payer engagement to accelerate development and adoption of oral complement therapies

Industry leaders should adopt a coordinated approach that aligns scientific, commercial, and operational initiatives to accelerate development and adoption of oral complement inhibitors. First, prioritize clinical programs that integrate biomarker-led patient selection and endpoint choices that matter to clinicians, regulators, and payers, thereby increasing the probability of clear, trustable clinical differentiation. Second, invest in formulation and pharmacokinetic optimization early to ensure oral candidates can achieve target engagement without compromising safety, and consider combination strategies that complement existing standards of care.

Operationally, companies should diversify supply chains and qualify multiple suppliers for critical intermediates and active ingredients to mitigate geopolitical and tariff-related risks. From a commercial perspective, developing robust health economic models and real-world evidence plans will facilitate reimbursement discussions and support value-based contracting where appropriate. Additionally, strengthen stakeholder engagement by involving patient advocacy groups, treating clinicians, and payers during development to ensure that trial designs and post-launch support align with real-world needs. Finally, consider modular launch plans that sequence indications and geographies based on clinical readiness, regulatory alignment, and payer receptivity to optimize resource allocation and market impact.

Comprehensive multi-source research methodology combining primary expert engagement, regulatory and clinical literature synthesis, and triangulated scenario analysis to support strategic conclusions

This analysis integrates a multi-source research methodology that combines primary expert interviews, systematic review of public clinical trial registries and regulatory publications, and synthesis of peer-reviewed translational and clinical literature. Primary qualitative inputs were obtained from clinicians specializing in hematology and immunology, pharmacology experts with complement experience, supply chain professionals, and payer representatives to ground findings in operational reality. Secondary research included analysis of recent scientific conferences, regulatory guidance documents, and published safety and efficacy reports to ensure the technical basis of insights.

Data triangulation was used to reconcile disparate sources and to surface consistent themes across clinical, commercial, and operational domains. Where evidence gaps existed, scenario-based analysis was employed to explore plausible outcomes and strategic responses. Limitations include the evolving nature of clinical pipelines and regulatory decisions, which may alter program trajectories; therefore, ongoing surveillance of late-stage trial readouts, approval actions, and real-world uptake metrics is recommended to refine strategic planning and to update risk assessments over time.

Synthesis of strategic priorities emphasizing scientific validation, payer-aligned evidence generation, and operational resilience to realize oral complement therapy potential

In conclusion, oral complement inhibitors represent a pivotal shift in the therapeutic management of complement-mediated disorders, offering the potential for improved convenience, adherence, and outpatient care models. Scientific progress in target validation and oral drug design, together with evolving regulatory and payer openness to patient-centered and real-world evidence, supports continued investment in these modalities. Nevertheless, successful translation to clinical use requires careful attention to patient stratification, chronic safety monitoring, and alignment with payer value frameworks.

Operational resilience is equally critical; supply chain diversification and regulatory foresight will mitigate tariff- and trade-related disruptions that can impact program timelines and patient access. Finally, collaborative approaches that combine the strengths of established industry players and agile innovators, anchored by rigorous evidence generation and stakeholder engagement, will be the most effective path to delivering durable clinical and commercial outcomes. Stakeholders who proactively integrate these considerations into development and launch planning will be best positioned to realize the promise of oral complement therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Complement Inhibitors Market, by Drug Class

  • 8.1. Avacopan
  • 8.2. Iptacopan

9. Oral Complement Inhibitors Market, by Molecular Target

  • 9.1. Factor D Inhibitors
  • 9.2. Factor B Inhibitors
  • 9.3. C5 Inhibitors

10. Oral Complement Inhibitors Market

  • 10.1. Hematological Disorders
  • 10.2. Renal Diseases
  • 10.3. Neurological Disorders
  • 10.4. Ophthalmological Diseases

11. Oral Complement Inhibitors Market, by Therapeutic Application

  • 11.1. Atypical Hemolytic Uremic Syndrome
    • 11.1.1. Adult Patients
    • 11.1.2. Pediatric Patients
  • 11.2. Hereditary Angioedema
    • 11.2.1. Acute Treatment
    • 11.2.2. Prophylactic Treatment
  • 11.3. Paroxysmal Nocturnal Hemoglobinuria
    • 11.3.1. Adult Patients
    • 11.3.2. Pediatric Patients

12. Oral Complement Inhibitors Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oral Complement Inhibitors Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oral Complement Inhibitors Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oral Complement Inhibitors Market

16. China Oral Complement Inhibitors Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Akari Therapeutics, Plc
  • 17.6. Alexion Pharmaceuticals, Inc.
  • 17.7. Amgen Inc.
  • 17.8. Apellis Pharmaceuticals, Inc.
  • 17.9. Biocryst Pharmaceuticals, Inc.
  • 17.10. ChemoCentryx, Inc.
  • 17.11. Ionis Pharmaceuticals, Inc.
  • 17.12. Johnson & Johnson Services, Inc.
  • 17.13. Merck & Co., Inc.
  • 17.14. Novartis AG
  • 17.15. Omeros Corporation
  • 17.16. Pfizer Inc.
  • 17.17. Regeneron Pharmaceuticals, Inc.
  • 17.18. Roche Holding AG
  • 17.19. Swedish Orphan Biovitrum AB
  • 17.20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY AVACOPAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY AVACOPAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY AVACOPAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY IPTACOPAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY IPTACOPAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY IPTACOPAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR D INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR D INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR D INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR B INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR B INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY FACTOR B INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY C5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY RENAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY RENAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PROPHYLACTIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 141. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 165. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 173. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY MOLECULAR TARGET, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY , 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY HEREDITARY ANGIOEDEMA, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ORAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)